Berardo C, Gerardi R, Delle Monache M, Del Vecchio S, Ricci G L
Divisione di Gastroenterologia, Università La Sapienza, Roma, Italy.
Ital J Gastroenterol. 1994 Oct-Nov;26(8):398-400.
The aim of the study was to investigate whether the immunoblot pattern for HCV is a predictor of the response to interferon treatment. In a group of 60 patients with persistent rise of aminotransferase, all were treated with 3-6MU of Alfa-IFN from normal leucocytes every other day for 6 months, followed by one weekly dose of 1-3 MU for 3 months. HCV serum markers were detected before treatment and every three months thereafter. In 22 out of 60 (36.6%) patients aminotransferase normalized and remained so for 3 months after therapy; 12 patients (54.5%) relapsed during a follow-up of 9-12 months. The most frequent pattern in responders and non responders was the positivity to four antibodies (55%). The pattern did not change during or after IFN therapy, nor was it related to the variation of aminotransferases. Three patients lost antibodies linked to viral replication (c100-3, 5-1-1) and 3 others became positive to the same antigens. No changes were observed during the follow-up of patients who had an initial normalization of ALT/AST levels and who then relapsed (either during the maintenance dose or during the whole follow-up:n = 19 pts). Therefore neither the antibody clearance of viral replication (c100-3 and 5-1-1) nor the antibody pattern is a valid predictor as to the efficacy of interferon therapy.
该研究的目的是调查丙型肝炎病毒（HCV）的免疫印迹模式是否可预测干扰素治疗的反应。在一组60例转氨酶持续升高的患者中，所有患者均每隔一天接受3-6MU来自正常白细胞的α-干扰素治疗，为期6个月，随后每周一次剂量为1-3MU，持续3个月。在治疗前及之后每三个月检测HCV血清标志物。60例患者中有22例（36.6%）转氨酶恢复正常并在治疗后3个月保持正常；12例患者（54.5%）在9至12个月的随访期间复发。应答者和非应答者中最常见的模式是四种抗体呈阳性（55%）。该模式在干扰素治疗期间或之后未发生变化，也与转氨酶的变化无关。3例患者失去了与病毒复制相关的抗体（c100-3、5-1-1），另外3例患者对相同抗原呈阳性。在最初ALT/AST水平恢复正常然后复发的患者随访期间（无论是在维持剂量期间还是在整个随访期间：n = 19例患者）未观察到变化。因此，病毒复制抗体（c100-3和5-1-1）的清除以及抗体模式均不是干扰素治疗疗效的有效预测指标。
